Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]

ClinicalTrials.gov ID: NCT02367794

Public ClinicalTrials.gov record NCT02367794. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 8:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel or Atezolizumab in Combination With Carboplatin+Nab-Paclitaxel Versus Carboplatin+Nab-Paclitaxel in Chemotherapy-Naive Patients With Stage IV Squamous Non-Small Cell Lung Cancer

Study identification

NCT ID
NCT02367794
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Hoffmann-La Roche
Industry
Enrollment
1,021 participants

Conditions and interventions

Interventions

  • Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody Drug
  • Carboplatin Drug
  • Nab-Paclitaxel Drug
  • Paclitaxel Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 10, 2015
Primary completion
Oct 2, 2018
Completion
Feb 16, 2021
Last update posted
Mar 20, 2022

2015 – 2021

United States locations

U.S. sites
57
U.S. states
28
U.S. cities
56
Facility City State ZIP Site status
Ironwood Cancer & Research Centers Chandler Arizona 85224
Highlands Oncology Group Springdale Arkansas 72762
Southern CA Permanente Med Grp Bellflower California
Kaiser Permanente Oakland Medical Center Oakland California 94611
Kaiser Permanente - Sacramento Medical Center and Medical Offices Sacramento California 95825
Kaiser Permanente - San Leandro Medical Center San Leandro California 94577
Kaiser Permanente - Santa Clara Santa Clara California 95051
Kaiser Permanente; Oncology Clinical Trials Vallejo California 94589
Kaiser Permanente - Walnut Creek Walnut Creek California 94596
Rocky Mountain Cancer Center Denver Colorado 80218
Danbury Hospital Danbury Connecticut 06810
Holy Cross Hospital Inc Fort Lauderdale Florida 33308
SCRI Florida Cancer Specialists South Fort Myers Florida 33916
Florida Cancer Specialists Palm Beach Gardens Florida 33410
Hematology Oncology Associates of the Treasure Coast Port Saint Lucie Florida 34952
Florida Cancer Specialists (St. Petersburg - St. Anthony's Professional Building) St. Petersburg Florida 33705
University Cancer & Blood Center, LLC; Research Athens Georgia 30607
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital Carrollton Georgia 30117
Central Georgia Cancer Care PC Macon Georgia 31201
Southeastern Regional Medical Center, Inc. Newnan Georgia 30265
University of Chicago Chicago Illinois 60637
Joliet Oncology-Hematology; Associates, Ltd. Joliet Illinois 60435
Quincy Medical Group Quincy Illinois 62301
Fort Wayne Med Oncology & Hematology Inc Fort Wayne Indiana 46845
Hematology-Oncology; Associates of the Quad Cities Bettendorf Iowa 52722
Siouxland Hematology/Oncology Sioux City Iowa 51101
Lahey Clinic Med Ctr Lexington Kentucky 02421
Norton Cancer Institute Louisville Kentucky 40202
Ochsner Clinic Foundation New Orleans Louisiana 70121
New England Cancer Specialists Scarborough Maine 04074
Southcoast Health System; Southcoast Centers For Cancer Care Fairhaven Massachusetts 02719
St. Joseph Mercy Health System Ann Arbor Michigan 48106
Karmanos Cancer Institute Detroit Michigan 48201
St. Luke's Regional Cancer Center Duluth Minnesota 55805
Hematology and Oncology Associates at Bridgepoint Tupelo Mississippi 38801
Billings Clinic Billings Montana 59102
Valley Hospital; Oncology Research Paramus New Jersey 07652
Regional Cancer Care Associates LLC Sewell New Jersey 08080
Clinical Research Alliance Westbury New York 11590
W.G. Bill Hefner VA Medical Center Salisbury North Carolina
University of Cincinnati Cincinnati Ohio 45203-0542
Mark H. Zangmeister Center Columbus Ohio 43219
Oncology Hematology Care, Inc. Hamilton Ohio 45103
Oregon Health & Science Uni Portland Oregon 97239
St. Luke's Cancer Care Associates Bethlehem Pennsylvania 18015
Maryland Oncology Hematology (Lanham) - USOR Gettysburg Pennsylvania 17325
Allegheny Cancer Center Pittsburgh Pennsylvania 15212
Univ of Pittsburgh Medical Ctr Pittsburgh Pennsylvania 15232
SCRI Tennessee Oncology Chattanooga Chattanooga Tennessee 37404
Tennessee Cancer Specialists Knoxville Tennessee 37920
SCRI The Center For Cancer and Blood Disorders Denton Texas 76210
Longview Cancer Center Longview Texas 75601
Virginia Cancer Specialists, PC Fairfax Virginia 22031
Virginia Oncology Associates Norfolk Virginia 23502
Blue Ridge Cancer Care Roanoke Virginia 24014
Providence Regional Cancer Partnership Everett Washington 98201
Medical Oncology Associates Spokane Washington 99208

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 185 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02367794, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 20, 2022 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02367794 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →